What happened with RVTY today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Revvity helps researchers develop drugs and healthcare professionals test for disease. Its two businesses contribute broadly similar amounts of revenue. Life Sciences sells tools for studying cells, genes and proteins to drugmakers, biotechnology companies, contract research organizations and public research institutions. Diagnostics supplies hospitals and medical laboratories with testing equipment and reagents, particularly for immune-related testing and screening from pregnancy through early childhood.
Customers pay for instruments, the reagents and other consumables used in their work, software and supporting services. Software subscriptions and service contracts also bring in revenue over time. In some diagnostic arrangements, Revvity keeps ownership of an instrument and lets the customer use it without a separate equipment fee, earning revenue instead from the reagents it supplies.
Demand depends on customers’ research funding, equipment budgets and the timing of purchases. Bringing new offerings to market can also depend on regulatory approvals, while restrictions on some licensed technologies limit the applications Revvity can develop or sell.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Bio-Rad and Revvity both depend on research laboratories buying biological instruments and reagents, and on clinical diagnostic testing demand. Watch Bio-Rad’s Life Science and Clinical Diagnostics sales separately to distinguish research spending from testing demand.
Bio-Techne competes with Revvity for spending on reagents and instruments used in protein and cell research, drug discovery and diagnostic testing. Its Protein Sciences sales offer the clearest read on the research side of that overlap.
Thermo Fisher and Revvity compete for pharmaceutical companies’, research institutions’ and clinical laboratories’ spending on life-science tools, diagnostic products and laboratory services. Thermo Fisher’s Life Sciences Solutions and Specialty Diagnostics results help separate research demand from clinical testing demand.
Danaher competes with Revvity through businesses selling life-science and diagnostic products, so research investment and testing demand matter to both. Watch its Life Sciences and Diagnostics results rather than treating its Biotechnology business as an equally close comparison.
QIAGEN and Revvity compete for research and diagnostic customers buying tools to process samples, run molecular tests and interpret results, including automation and software. Watch QIAGEN’s consumables revenue for a read on ongoing molecular testing demand, distinct from instrument purchases.
Agilent and Revvity compete for research and clinical laboratories’ purchases of cell-analysis, genomics, laboratory software and diagnostic solutions. Watch those offerings rather than Agilent’s instrument sales alone: its CrossLab consumables can serve laboratories regardless of which instruments they choose.
Waters names Revvity as a rival in instrument services and the markets served by its BDS business; Revvity can provide some services on Waters instruments. Watch Waters’ paid maintenance and repair revenue for evidence of competition for laboratory service spending.
QuidelOrtho Corporation competes with Revvity to supply clinical laboratories with diagnostic instruments and repeat purchases of tests and reagents. Watch its assay and reagent demand: some customers buy these under long-term instrument contracts, making testing activity important beyond new equipment sales.
Bruker and Revvity compete for overlapping laboratories’ spending on instruments and analytical solutions for biological research and clinical diagnostics. Bruker’s news on life-science and diagnostic products is more relevant to Revvity than its materials-science offerings.
Avantor’s laboratory supplies depend on spending in the same biopharmaceutical and academic research markets that buy Revvity’s life-science tools. Its Laboratory Solutions sales, including reagents, consumables and equipment distributed through VWR, offer a read on those customers’ purchasing demand.
Illumina’s sequencing systems and Revvity’s applied-genomics tools serve research and clinical laboratories using next-generation DNA sequencing, tying both to spending on those workflows. Watch Illumina’s sequencing instruments and consumables for demand relevant to Revvity’s applied-genomics business, most of which sits in Life Sciences from fiscal 2025.
Natera names Revvity as a competitor in non-invasive prenatal testing, directly linking its prenatal tests sold through laboratories and distribution partners to Revvity’s reproductive-health business. Watch Natera’s prenatal-testing news rather than its cancer or transplant tests for this rivalry.
Schrodinger, Inc. competes with Revvity for biopharmaceutical companies’ spending on simulation, modeling and enterprise life-science software. Watch its pharmaceutical software customers and license revenue for a comparison with Revvity’s Software business, rather than its laboratory instrument demand.
Cytek Biosciences, Inc. competes for the pharmaceutical, academic and clinical laboratories’ cell-analysis spending that also supports Revvity’s cell-research products. Watch both its instrument sales and reagents bought for installed systems to distinguish equipment purchases from ongoing cell-analysis activity.
Thermo Fisher Scientific, Inc. earningsTMO
Thermo Fisher's Life Sciences Solutions and Specialty Diagnostics results will show whether research and clinical-lab spending is holding up in markets Revvity also serves.
Read Thermo Fisher's Life Sciences Solutions and Specialty Diagnostics results separately, then relate them to Revvity's Life Sciences and Diagnostics businesses. Strength in the first points to firmer spending on research tools; strength in the second points to steadier clinical-diagnostic demand. Weakness in either flags pressure in the corresponding customer market, while mixed results mean one company's overall performance cannot stand in for all of Revvity. The takeaway is which market—research or clinical testing—looks more resilient.
Avantor, Inc. earningsAVTR
Avantor's Laboratory Solutions sales will show whether biopharma and academic labs that buy Revvity research tools are still purchasing everyday supplies and equipment.
Watch the direction of Avantor's Laboratory Solutions sales, including demand for lab reagents, consumables and equipment. Steady or rising sales would suggest biopharma and academic labs are still buying, supporting the customer environment for Revvity's research tools. Falling sales would point to more cautious or delayed purchasing, which could also weigh on demand for Revvity instruments and reagents. Avantor distributes a range of products through VWR, so this is a read on customer purchasing, not a direct substitute for Revvity's sales.
Illumina Inc earningsILMN
Illumina's sequencing-instrument and consumables sales will show whether research and clinical labs are still investing in workflows that also use Revvity's applied-genomics tools.
Read Illumina's sequencing-instrument sales alongside demand for consumables. Strength in both would show labs are adding equipment and continuing to run sequencing workflows, supporting demand relevant to Revvity's applied-genomics business. Strong instrument sales but weak consumables demand would mean new equipment is not necessarily translating into ongoing use, so instrument purchases alone would overstate the signal. The conclusion is whether these labs are investing both in new systems and in continued workflow activity.
Revvity, Inc. earningsThis company
Revvity sells instruments, reagents and software to research and diagnostic customers, and its report will show whether demand in both businesses can support revenue and gross margin.
Read Life Sciences and Diagnostics revenue alongside gross margin. Growth in both businesses with a stable or improving margin would show that demand for research tools and diagnostic products is supporting sales without costs taking a larger share. If growth comes from only one business, or weaker revenue comes with a falling margin, demand may be uneven and costs or product mix may be squeezing profit. The conclusion is whether Revvity can turn sales across both businesses into a steadier gross margin.
Waters Corp earningsWAT
Waters' paid maintenance and repair revenue will show whether labs are still paying for instrument service in a market where Revvity also competes.
See whether Waters' paid maintenance and repair revenue is growing or weakening. Growth would show that customers are still paying to maintain and repair instruments, while Waters' service revenue on its systems also reflects competition for spending that Revvity can pursue. Weakness could mean labs are cutting or delaying repair work. The conclusion is whether service demand is holding up and how Waters is doing in that competitive market—not how much service revenue Revvity itself earns.
QuidelOrtho Corporation earningsQDEL
QuidelOrtho's test and reagent demand will show whether clinical labs are continuing to run tests in a market that overlaps with Revvity's diagnostic instruments and consumables.
Separate QuidelOrtho's test and reagent demand from new instrument sales. Steady demand would show that labs are continuing to run tests and repeat purchases remain supported; weakness could pressure reagent use and related sales even where instruments are already installed. Some customers buy tests under long-term instrument contracts, so consumables reveal ongoing testing better than new equipment alone. The takeaway is whether recurring clinical-testing activity is holding up, and what that may mean for pressure on Revvity's diagnostic consumables in an overlapping market.
Schrodinger, Inc. earningsSDGR
Schrodinger's pharmaceutical software customers and license revenue will show whether drug companies are still paying for life-science software in an area that overlaps with Revvity's Software business.
Watch Schrödinger's software revenue and license sales to pharmaceutical customers. Growth would suggest drug companies are still paying for life-science software, supporting the budget environment for Revvity's Software business; weakness would point to tighter software spending. The companies' tools are not identical, so this is a read on spending in an adjacent software market, not a direct substitute for Revvity's software sales. The takeaway is the direction of pharmaceutical investment in life-science software.
Natera, Inc. earningsNTRA
Natera's prenatal-testing business will show demand in a market where it directly competes with Revvity's reproductive-health business, as well as the rival's momentum for those customers.
Focus on Natera's prenatal testing, not its cancer or transplant tests. Strength would show that demand in this market is supported, but Natera is also competing for customers in the market served by Revvity's reproductive-health business. Weakness could mean less momentum from a rival, but it could also signal a softer prenatal-testing market overall. The conclusion is to separate market demand from the competitor's progress: Natera's growth does not automatically mean Revvity lost the same amount of business.
